Market Overview

Fatty Acid Amide Hydrolase (FAAH) Inhibitors - Pipeline Insights, 2018 -


The "Fatty
Acid Amide Hydrolase (FAAH) Inhibitors- Pipeline Insights, 2018"

report has been added to's

This report outlays comprehensive insights of present scenario and
growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor.

A detailed picture of the pipeline landscape is provided with summation
of data from multiple sources with complete analysis by development
stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 5+ active products with more
than 5 companies involved. Two of the key players include PF-04457845 of
Spring Works Therapeutics and JNJ-42165279 of Janssen.

Products covered by Phase

  • Phase II
  • Pre-clinical
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Fatty Acid Amide
Hydrolase (FAAH) Inhibitors

  • Pipeline analysis of therapeutic drugs include but are not limited to
    drug description and development activities focusing on clinical and
    pre-clinical results, designations, collaborations & licensing deals,
    grants, technology and patent details.
  • Therapeutic segmentation of products for Fatty Acid Amide Hydrolase
    (FAAH) Inhibitors.
  • The report comprises of comparative pipeline therapeutics assessment
    by development stage, therapy type, molecule type, and administration
    route across this mechanism.


  • Provides an overview of therapeutic pipeline activity for Fatty Acid
    Amide Hydrolase (FAAH) Inhibitors across the complete product
    development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Fatty Acid Amide Hydrolase (FAAH)
    Inhibitors therapeutic products with key coverage of developmental
    activities including licensing & collaboration deals, patents issued,
    designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage,
    product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Fatty
    Acid Amide Hydrolase (FAAH) Inhibitors

Key Topics Covered

  1. Overview
  2. Introduction
  3. Oleamide and Anandamide
  4. Function of Fatty acid amide hydrolase (FAAH)
  5. Structure of FAAH
  6. Mechanism of Action of FAAH
  7. Fatty acid amide hydrolase (FAAH) Inhibitor
  8. Future Scope for FAAH Inhibitor
  9. Emergence of FAAH Inhibitors
  10. Pipeline Therapeutics (Active Products)
  11. Pipeline Therapeutics (Inactive Products)
  12. Comparative Analysis
  13. Mid Stage Products (Phase II)
  14. Comparative Analysis
  15. JNJ 42165279: Janssen
  16. Product Description
  17. Research and Development
  18. The list continues..
  19. Early Stage Products (Phase I)
  20. Comparative Analysis
  21. Pre-clinical and Discovery Stage Products
  22. Comparative Analysis
  23. Therapeutic Assessment: Active Products
  24. Assessment by Stage and Product Type
  25. Assessment by Route of Administration
  26. Assessment by Stage and Route of Administration
  27. Assessment by Molecule Type
  28. Assessment by Stage and Molecule Type
  29. Inactive Products
  30. Comparative Analysis
  31. Appendix

Companies Featured

  • Exxel Phrma
  • Janssen
  • MAKscientific
  • Pfizer
  • Scythian Biosciences
  • Bial pharmaceuticals
  • Infinity Pharmaceuticals
  • Iron Wood Pharma
  • Johnson and Johnson
  • Leadiant Biosciences
  • Makscientific
  • Merck
  • Pfizer
  • Renovis
  • Sanofi
  • Vernalis

For more information about this report visit

View Comments and Join the Discussion!